August 8, 2002Open Access

Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

In patients with invasive aspergillosis, initial therapy with voriconazole led to better responses and improved survival and resulted in fewer severe side effects than the standard approach of initial therapy with amphotericin B.

Leer artículo completoexternamente

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Herbrecht et al. (Thu,) studied this question.

synapsesocial.com/papers/69d818f533ca018b39ae34fd https://doi.org/https://doi.org/10.1056/nejmoa020191

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1On the Use of Pocock and Simon's Method for Balancing Treatment Numbers over Prognostic Factors in the Controlled Clinical Trial1976 · 131 citations
2Invasive pulmonary aspergillosis in acute leukemia: characteristic findings on CT, the CT halo sign, and the role of CT in early diagnosis.1985 · 452 citations
3Amphotericin B colloidal dispersion vs. amphotericin B as therapy for invasive aspergillosis.1997 · 168 citations
4Invasive Aspergillosis1998 · 1,489 citations
5Editorial Response: The Contribution of Fluconazole to the Changing Epidemiology of Invasive Candidal Infections1997 · 151 citations

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo